Hepatera

Executive Summary

Hepatera is a private European biopharmaceutical company headquartered in Moscow, Russia, founded in 2010 with a focus on developing novel antiviral therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV). The company's lead asset is a first-in-class NTCP (sodium taurocholate cotransporting polypeptide) inhibitor designed to block viral entry into liver cells. This mechanism represents a novel approach to treating chronic HBV and HDV infections, which are significant global health burdens affecting millions worldwide. Current standard of care for HBV includes nucleos(t)ide analogs and pegylated interferon, but these rarely achieve functional cure, and there are no approved therapies specifically for HDV. Hepatera's NTCP inhibitor aims to address this unmet need by preventing viral entry and potentially enabling functional cure. The company is privately held and has not disclosed specific funding amounts or valuation. As a preclinical or early clinical-stage company, its success hinges on advancing the lead asset through clinical trials and securing partnerships or additional financing. The company's location in Russia may present regulatory and operational challenges but also offers access to a large patient population for HBV/HDV. Hepatera's pipeline appears focused on this single asset, making it a high-risk, high-reward investment opportunity contingent on clinical proof-of-concept.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1/2 clinical trial for lead NTCP inhibitor40% success
• Q4 2026Announcement of preclinical efficacy data in HDV models50% success
• Q1 2027Partnership or licensing deal for HBV/HDV asset30% success